Literature DB >> 23806582

Persecutory ideation and a history of cannabis use.

Daniel Freeman1, Paul D Morrison, Robin M Murray, Nicole Evans, Rachel Lister, Graham Dunn.   

Abstract

BACKGROUND: Cannabis use is associated with the occurrence of psychotic experiences. However there are multiple distinct psychotic experiences, each likely to occur as quantitative traits in the general population. In this study we tested for an association of cannabis use with a dimensional assessment of persecutory ideation.
METHOD: A total of 1714 individuals from the general population completed a dimensional measure of current persecutory ideation and reported on whether they had ever taken cannabis.
RESULTS: Of all participants, 648 (38%) reported a history of cannabis use. These individuals reported significantly higher current levels of persecutory ideation. The amount of variance in paranoia scores explained was low. Individuals with a history of cannabis use had almost twice the odds of reporting any paranoid ideation in the past month compared with individuals who had never taken cannabis.
CONCLUSIONS: Using a state of the art assessment, the study adds to findings of an association of persecutory ideation with cannabis use.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cannabis; Delusions; Paranoia; Persecutory ideation

Mesh:

Year:  2013        PMID: 23806582     DOI: 10.1016/j.schres.2013.06.008

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  6 in total

1.  Delusions in first-episode psychosis: Principal component analysis of twelve types of delusions and demographic and clinical correlates of resulting domains.

Authors:  Enrico Paolini; Patrizia Moretti; Michael T Compton
Journal:  Psychiatry Res       Date:  2016-06-11       Impact factor: 3.222

2.  The revised Green et al., Paranoid Thoughts Scale (R-GPTS): psychometric properties, severity ranges, and clinical cut-offs.

Authors:  Daniel Freeman; Bao S Loe; David Kingdon; Helen Startup; Andrew Molodynski; Laina Rosebrock; Poppy Brown; Bryony Sheaves; Felicity Waite; Jessica C Bird
Journal:  Psychol Med       Date:  2019-11-20       Impact factor: 7.723

3.  Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank.

Authors:  Michael Wainberg; Grace R Jacobs; Marta di Forti; Shreejoy J Tripathy
Journal:  Transl Psychiatry       Date:  2021-04-09       Impact factor: 6.222

4.  How cannabis causes paranoia: using the intravenous administration of ∆9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia.

Authors:  Daniel Freeman; Graham Dunn; Robin M Murray; Nicole Evans; Rachel Lister; Angus Antley; Mel Slater; Beata Godlewska; Robert Cornish; Jonathan Williams; Martina Di Simplicio; Artemis Igoumenou; Rudolf Brenneisen; Elizabeth M Tunbridge; Paul J Harrison; Catherine J Harmer; Philip Cowen; Paul D Morrison
Journal:  Schizophr Bull       Date:  2014-07-15       Impact factor: 9.306

Review 5.  The neuropsychopharmacology of cannabis: A review of human imaging studies.

Authors:  Michael A P Bloomfield; Chandni Hindocha; Sebastian F Green; Matthew B Wall; Rachel Lees; Katherine Petrilli; Harry Costello; M Olabisi Ogunbiyi; Matthijs G Bossong; Tom P Freeman
Journal:  Pharmacol Ther       Date:  2018-10-19       Impact factor: 12.310

Review 6.  The Construct of Medical and Non-Medical Marijuana-Critical Review.

Authors:  Andrzej Silczuk; Daria Smułek; Marcin Kołodziej; Julia Gujska
Journal:  Int J Environ Res Public Health       Date:  2022-02-27       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.